Skip to main content
Erschienen in: Tumor Biology 10/2016

28.07.2016 | Original Article

Downregulated expression of DIXDC1 in hepatocellular carcinoma and its correlation with prognosis

verfasst von: Senjun Zhou, Jiliang Shen, Shuang Lin, Xiaolong Liu, Ming Xu, Liang Shi, Xianfa Wang, Xiujun Cai

Erschienen in: Tumor Biology | Ausgabe 10/2016

Einloggen, um Zugang zu erhalten

Abstract

Dishevelled-Axin domain containing 1 (DIXDC1) is a DIX (Dishevelled-Axin) domain possessing protein that acts as a positive regulator of the Wnt pathway. Although DIXDC1 has been investigated in several cancers, it has not yet been studied in human hepatocellular carcinoma (HCC). The purpose of the current study was to investigate the expression pattern of DIXDC1 and assess the clinical significance of DIXDC1 expression in HCC patients. Data containing three independent investigations from Oncomine database demonstrated that DIXDC1 mRNA was downregulated in HCC compared with matched non-cancerous tissues. Similar results were also obtained in 25 paired HCC tissues and corresponding non-cancerous tissues by qPCR and Western blot analysis. Additionally, another independent set of 140 pairs of HCC specimens was evaluated for DIXDC1 expression by IHC and demonstrated that reduced expression of DIXDC1 in 50.7 % (71/140) of HCC tissues was significantly correlated with tumor size (p = 0.024), tumor differentiation (p < 0.001), tumor thrombi (p = 0.019), TNM stage (p = 0.019), and BCLC stage (p = 0.008). Importantly, Kaplan–Meier survival and Cox regression analyses were executed to evaluate the prognosis of HCC patients and found that DIXDC1 protein expression was one of the independent prognostic factors for overall survival of HCC patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics. CA Cancer J Clin. 2012;2015(65):87–108. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics. CA Cancer J Clin. 2012;2015(65):87–108.
3.
Zurück zum Zitat Pan HW, YH O, Peng SY, Liu SH, Lai PL, Lee PH, Sheu JC, Chen CL, Hsu HC. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer. 2003;98:119–27.CrossRefPubMed Pan HW, YH O, Peng SY, Liu SH, Lai PL, Lee PH, Sheu JC, Chen CL, Hsu HC. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer. 2003;98:119–27.CrossRefPubMed
4.
Zurück zum Zitat Goodwin JM, Svensson RU, Lou HJ, Winslow MM, Turk BE, Shaw RJ. An AMPK-independent signaling pathway downstream of the LKB1 tumor suppressor controls Snail1 and metastatic potential. Mol Cell. 2014;55:436–50.CrossRefPubMedPubMedCentral Goodwin JM, Svensson RU, Lou HJ, Winslow MM, Turk BE, Shaw RJ. An AMPK-independent signaling pathway downstream of the LKB1 tumor suppressor controls Snail1 and metastatic potential. Mol Cell. 2014;55:436–50.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Shiomi K, Uchida H, Keino-Masu K, Masu M. Ccd1, a novel protein with a DIX domain, is a positive regulator in the Wnt signaling during zebrafish neural patterning. Curr Biol. 2003;13:73–7.CrossRefPubMed Shiomi K, Uchida H, Keino-Masu K, Masu M. Ccd1, a novel protein with a DIX domain, is a positive regulator in the Wnt signaling during zebrafish neural patterning. Curr Biol. 2003;13:73–7.CrossRefPubMed
6.
Zurück zum Zitat Singh KK, Ge X, Mao Y, Drane L, Meletis K, Samuels BA, Tsai LH. Dixdc1 is a critical regulator of DISC1 and embryonic cortical development. Neuron. 2010;67:33–48.CrossRefPubMedPubMedCentral Singh KK, Ge X, Mao Y, Drane L, Meletis K, Samuels BA, Tsai LH. Dixdc1 is a critical regulator of DISC1 and embryonic cortical development. Neuron. 2010;67:33–48.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Kivimäe S, Martin PM, Kapfhamer D, Ruan Y, Heberlein U, Rubenstein JL, Cheyette BN. Abnormal behavior in mice mutant for the Disc1 binding partner, Dixdc1. Transl Psychiatry. 2011;1:e43.CrossRefPubMedPubMedCentral Kivimäe S, Martin PM, Kapfhamer D, Ruan Y, Heberlein U, Rubenstein JL, Cheyette BN. Abnormal behavior in mice mutant for the Disc1 binding partner, Dixdc1. Transl Psychiatry. 2011;1:e43.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Shiomi K, Kanemoto M, Keino-Masu K, Yoshida S, Soma K, Masu M. Identification and differential expression of multiple isoforms of mouse Coiled-coil-DIX1 (Ccd1), a positive regulatorof Wnt signaling. Mol Brain Res. 2005;135:169–80.CrossRefPubMed Shiomi K, Kanemoto M, Keino-Masu K, Yoshida S, Soma K, Masu M. Identification and differential expression of multiple isoforms of mouse Coiled-coil-DIX1 (Ccd1), a positive regulatorof Wnt signaling. Mol Brain Res. 2005;135:169–80.CrossRefPubMed
9.
Zurück zum Zitat Wang X, Zheng L, Zeng Z, Zhou G, Chien J, Qian C, Vasmatzis G, Shridhar V, Chen L, Liu W. DIXDC1 isoform, l-DIXDC1, is a novel filamentous actin-binding protein. Biochem Biophys Res Commun. 2006;347:22–30.CrossRefPubMed Wang X, Zheng L, Zeng Z, Zhou G, Chien J, Qian C, Vasmatzis G, Shridhar V, Chen L, Liu W. DIXDC1 isoform, l-DIXDC1, is a novel filamentous actin-binding protein. Biochem Biophys Res Commun. 2006;347:22–30.CrossRefPubMed
10.
Zurück zum Zitat Tan C, Qiao F, Wei P, Chi Y, Wang W, Ni S, Wang Q, Chen T, Sheng W, Du X, Wang L. DIXDC1 activates the Wnt signaling pathway and promotes gastric cancer cell invasion and metastasis. Mol Carcinog. 2016;55:397–408.CrossRefPubMed Tan C, Qiao F, Wei P, Chi Y, Wang W, Ni S, Wang Q, Chen T, Sheng W, Du X, Wang L. DIXDC1 activates the Wnt signaling pathway and promotes gastric cancer cell invasion and metastasis. Mol Carcinog. 2016;55:397–408.CrossRefPubMed
11.
Zurück zum Zitat Wang L, Tan C, Qiao F, Wang W, Jiang X, Lian P, Chang B, Sheng W. Upregulated expression of DIXDC1 in intestinal-type gastric carcinoma co-localization with β-catenin and correlation with poor prognosis. Cancer Cell Int. 2015;15:120.CrossRefPubMedPubMedCentral Wang L, Tan C, Qiao F, Wang W, Jiang X, Lian P, Chang B, Sheng W. Upregulated expression of DIXDC1 in intestinal-type gastric carcinoma co-localization with β-catenin and correlation with poor prognosis. Cancer Cell Int. 2015;15:120.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Xu Z, Liu D, Fan C, Luan L, Zhang X, Wang E. DIXDC1 increases the invasion and migration ability of non-small-cell lung cancer cells via the PI3K-AKT-AP-1 pathway. Mol Carcinog. 2014;53:917–25.CrossRefPubMed Xu Z, Liu D, Fan C, Luan L, Zhang X, Wang E. DIXDC1 increases the invasion and migration ability of non-small-cell lung cancer cells via the PI3K-AKT-AP-1 pathway. Mol Carcinog. 2014;53:917–25.CrossRefPubMed
13.
Zurück zum Zitat Wang L, Cao XX, Chen Q, Zhu TF, Zhu HG, Zheng L. DIXDC1 targets p21 and cyclin D1 via PI3K pathway activation to promote colon cancer cell proliferation. Cancer Sci. 2009;100:1801–8.CrossRefPubMed Wang L, Cao XX, Chen Q, Zhu TF, Zhu HG, Zheng L. DIXDC1 targets p21 and cyclin D1 via PI3K pathway activation to promote colon cancer cell proliferation. Cancer Sci. 2009;100:1801–8.CrossRefPubMed
14.
Zurück zum Zitat Wang L, Li H, Chen Q, Zhu T, Zhu H, Zheng L. Wnt signaling stabilizes the DIXDC1 protein through decreased ubiquitin-dependent degradation. Cancer Sci. 2010;101:700–6.CrossRefPubMed Wang L, Li H, Chen Q, Zhu T, Zhu H, Zheng L. Wnt signaling stabilizes the DIXDC1 protein through decreased ubiquitin-dependent degradation. Cancer Sci. 2010;101:700–6.CrossRefPubMed
15.
Zurück zum Zitat Edge SB, Byrd DR, Compton CC et al (eds) (2009) AJCC cancer staging manual, 7th edn. Springer, New York Edge SB, Byrd DR, Compton CC et al (eds) (2009) AJCC cancer staging manual, 7th edn. Springer, New York
16.
Zurück zum Zitat Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:698–711.CrossRefPubMed Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:698–711.CrossRefPubMed
17.
Zurück zum Zitat Tang L, Tan YX, Jiang BG, Pan YF, Li SX, Yang GZ, et al. The prognostic significance and therapeutic potential of hedgehog signaling in intrahepatic cholangiocellular carcinoma. Clin Cancer Res. 2013;19:2014–24.CrossRefPubMed Tang L, Tan YX, Jiang BG, Pan YF, Li SX, Yang GZ, et al. The prognostic significance and therapeutic potential of hedgehog signaling in intrahepatic cholangiocellular carcinoma. Clin Cancer Res. 2013;19:2014–24.CrossRefPubMed
18.
Zurück zum Zitat Luo RZ, Cai PQ, Li M, Fu J, Zhang ZY, Chen JW, Cao Y, Yun JP, Xie D, Cai MY. Decreased expression of PTPN12 correlates with tumor recurrence and poor survival of patients with hepatocellular carcinoma. PLoS One. 2014;9(1):e85592.CrossRefPubMedPubMedCentral Luo RZ, Cai PQ, Li M, Fu J, Zhang ZY, Chen JW, Cao Y, Yun JP, Xie D, Cai MY. Decreased expression of PTPN12 correlates with tumor recurrence and poor survival of patients with hepatocellular carcinoma. PLoS One. 2014;9(1):e85592.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Llovet JM1, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX,et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698–711. Llovet JM1, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX,et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698–711.
20.
Zurück zum Zitat Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med. 2006;12:410–6.CrossRefPubMed Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med. 2006;12:410–6.CrossRefPubMed
21.
22.
Zurück zum Zitat Liu YT, Dan QJ, Wang J, Feng Y, Chen L, Liang J, Li Q, Lin SC, Wang ZX, Wu JW. Molecular basis of Wnt activation via the DIX domain protein Ccd1. J Biol Chem 2011; 286: 8597–8608. Liu YT, Dan QJ, Wang J, Feng Y, Chen L, Liang J, Li Q, Lin SC, Wang ZX, Wu JW. Molecular basis of Wnt activation via the DIX domain protein Ccd1. J Biol Chem 2011; 286: 8597–8608.
23.
Zurück zum Zitat Wong CK, Luo W, Deng Y, Zou H, Ye Z, Lin SC. The DIX domain protein coiled-coil-DIX1 inhibits c-Jun N-terminal kinase activation by axin and dishevelled through distinct mechanisms. J Biol Chem. 2004;279:39366–73.CrossRefPubMed Wong CK, Luo W, Deng Y, Zou H, Ye Z, Lin SC. The DIX domain protein coiled-coil-DIX1 inhibits c-Jun N-terminal kinase activation by axin and dishevelled through distinct mechanisms. J Biol Chem. 2004;279:39366–73.CrossRefPubMed
24.
Zurück zum Zitat Wu Y, Jing X, Ma X, Wu Y, Ding X, Fan W, Fan M. DIXDC1 co-localizes and interacts with gamma-tubulin in HEK293 cells. Cell Biol Int. 2009;33:697–701.CrossRefPubMed Wu Y, Jing X, Ma X, Wu Y, Ding X, Fan W, Fan M. DIXDC1 co-localizes and interacts with gamma-tubulin in HEK293 cells. Cell Biol Int. 2009;33:697–701.CrossRefPubMed
25.
Zurück zum Zitat Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35:519–24.CrossRefPubMed Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35:519–24.CrossRefPubMed
26.
Zurück zum Zitat Ajay D. Staging of hepatocellular carcinoma. J Clin Exp Hepatol. 2014;4(Suppl 3):S74–9. Ajay D. Staging of hepatocellular carcinoma. J Clin Exp Hepatol. 2014;4(Suppl 3):S74–9.
27.
Zurück zum Zitat Aravalli RN, Cressman EN, Steer CJ. Cellular and molecular mechanisms of hepatocellular carcinoma: an update. Arch Toxicol. 2013;87:227–47.CrossRefPubMed Aravalli RN, Cressman EN, Steer CJ. Cellular and molecular mechanisms of hepatocellular carcinoma: an update. Arch Toxicol. 2013;87:227–47.CrossRefPubMed
28.
Zurück zum Zitat Funasaka T, Hogan V, Raz A. Phosphoglucose isomerase/autocrine motility factor mediates epithelial and mesenchymal phenotype conversions in breast cancer. Cancer Res. 2009;69:5349–56.CrossRefPubMedPubMedCentral Funasaka T, Hogan V, Raz A. Phosphoglucose isomerase/autocrine motility factor mediates epithelial and mesenchymal phenotype conversions in breast cancer. Cancer Res. 2009;69:5349–56.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Lee BY, Timpson P, Horvath LG, Daly RJ. FAK signaling in human cancer as a target for therapeutics. Pharmacol Ther. 2015;146:132–49.CrossRefPubMed Lee BY, Timpson P, Horvath LG, Daly RJ. FAK signaling in human cancer as a target for therapeutics. Pharmacol Ther. 2015;146:132–49.CrossRefPubMed
30.
Zurück zum Zitat Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell. 2004;5:215–9.CrossRefPubMed Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell. 2004;5:215–9.CrossRefPubMed
31.
Zurück zum Zitat A Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J. EASL panel of experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421–30.CrossRefPubMed A Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J. EASL panel of experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421–30.CrossRefPubMed
Metadaten
Titel
Downregulated expression of DIXDC1 in hepatocellular carcinoma and its correlation with prognosis
verfasst von
Senjun Zhou
Jiliang Shen
Shuang Lin
Xiaolong Liu
Ming Xu
Liang Shi
Xianfa Wang
Xiujun Cai
Publikationsdatum
28.07.2016
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 10/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5213-9

Weitere Artikel der Ausgabe 10/2016

Tumor Biology 10/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.